SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 816.18 |
| Enterprise Value ($M) | 823.91 |
| Book Value ($M) | 74.66 |
| Book Value / Share | 0.77 |
| Price / Book | 10.93 |
| NCAV ($M) | 43.67 |
| NCAV / Share | 0.45 |
| Price / NCAV | 18.69 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.64 |
| Return on Assets (ROA) | -0.44 |
| Return on Equity (ROE) | -0.83 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 2.60 |
| Current Ratio | 2.97 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 127.26 |
| Assets | 158.25 |
| Liabilities | 83.59 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Janus Henderson Group Plc | |||
| 13G/A | Rtw Investments, Lp | 0.00 | -100.00 | |
| 13G/A | Polar Capital Holdings Plc | 4.99 | -28.85 | |
| 13G/A | Cowen And Company, Llc | 0.00 | -100.00 | |
| 13G | BlackRock, Inc. | 5.50 | 0.00 | |
| 13G/A | Gendell Jeffrey L | 6.33 | 9.53 | |
| 13G/A | Kotler Kevin | 4.10 | 19.03 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 177,860 | 1,273,860 | 13.96 | |
| 154,267 | 872,370 | 17.68 | |
| 130,523 | 617,498 | 21.14 | |
| 158,677 | 1,127,167 | 14.08 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| AUPH – Aurinia Pharmaceuticals Inc. | AURA – Aura Biosciences, Inc. |
| AVBP – ArriVent BioPharma, Inc. | AVTE – Aerovate Therapeutics, Inc. |
| AXSM – Axsome Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io